AKROS PHARMA INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects

Phase 1

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: JTT-251 or Placebo

First Posted Date: 2014-04-08

Last Posted Date: 2014-10-07

Lead Sponsor: Akros Pharma Inc.

Target Recruit Count: 94

Registration Number: NCT02106585

Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease

Phase 1

Completed

Conditions: Anemia in Chronic Kidney Disease

Interventions: Drug: JTZ-951

First Posted Date: 2013-11-07

Last Posted Date: 2014-03-18

Lead Sponsor: Akros Pharma Inc.

Target Recruit Count: 6

Registration Number: NCT01978587

Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease

Phase 1

Completed

Conditions: Anemia of Chronic Kidney Disease

Interventions: Drug: JTZ-951
Drug: Placebo

First Posted Date: 2013-10-29

Last Posted Date: 2014-07-14

Lead Sponsor: Akros Pharma Inc.

Target Recruit Count: 29

Registration Number: NCT01971164

Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: JTT-851
Drug: Glimepiride
Drug: Placebo for comparator
Drug: Placebo for Active

First Posted Date: 2012-10-04

Last Posted Date: 2013-08-01

Lead Sponsor: Akros Pharma Inc.

Target Recruit Count: 325

Registration Number: NCT01699737

Safety, Tolerability and Pharmacokinetics Study Assessing Ascending Single Oral JTK-853 Doses in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JTK-853 or Placebo

First Posted Date: 2011-11-22

Last Posted Date: 2011-11-22

Lead Sponsor: Akros Pharma Inc.

Target Recruit Count: 70

Registration Number: NCT01475981

Locations: 🇺🇸
PPD, Phase I Clinic, Austin, Texas, United States

Two Week Study Evaluating Safety, Tolerability and Pharmacokinetics of Multiple Doses of JTK-853 in Healthy Subjects

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: JTK-853, ketoconazole
Drug: JTK-853 or Placebo

First Posted Date: 2011-11-17

Last Posted Date: 2011-11-21

Lead Sponsor: Akros Pharma Inc.

Target Recruit Count: 41

Registration Number: NCT01473069

Locations: 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States

Study to Assess Safety,Tolerability,Pharmacokinetics & Antiviral Activity of JTK-853 in Hepatitis C Virus Genotype 1 Infected Subjects

Phase 1

Completed

Conditions: Hepatitis C Virus Infection, Response to Therapy of

Interventions: Drug: JTK-853
Drug: Dose 2 JTK-853
Drug: Dose 3 JTK-853
Drug: Dose 4 JTK-853
Drug: Placebo

First Posted Date: 2011-11-17

Last Posted Date: 2011-11-21

Lead Sponsor: Akros Pharma Inc.

Target Recruit Count: 29

Registration Number: NCT01473056

Locations: 🇵🇷
Fundacion de Investigacion de Diego, San Juan, Puerto Rico

Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients

Phase 2

Terminated

Conditions: Type II Diabetes Mellitus

Interventions: Drug: JTT-654
Drug: JTT-654 Placebo

First Posted Date: 2009-10-19

Last Posted Date: 2013-02-04

Lead Sponsor: Akros Pharma Inc.

Target Recruit Count: 152

Registration Number: NCT00997152

Safety and Efficacy Study of JTT-130 in Obese Type 2 Diabetic Patients

Phase 2

Completed

Conditions: Type II Diabetes Mellitus

Interventions: Drug: JTT-130
Drug: JTT-130 Placebo

First Posted Date: 2009-06-29

Last Posted Date: 2013-02-04

Lead Sponsor: Akros Pharma Inc.

Target Recruit Count: 496

Registration Number: NCT00929539

Efficacy and Safety Study of JTT-302 in Subjects With Low HDL-C Levels

Phase 2

Completed

Conditions: Dyslipidemia

Interventions: Drug: JTT-302
Drug: Placebo

First Posted Date: 2008-09-09

Last Posted Date: 2013-02-04

Lead Sponsor: Akros Pharma Inc.

Target Recruit Count: 150

Registration Number: NCT00749788

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy